Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; STK-012 (Primary)
  • Indications Cervical cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Synthekine

    • Most Recent Events

    • 10 Apr 2024 Results presented at the 115th Annual Meeting of the American Association for Cancer Research
    • 09 Apr 2024 According to a Synthekine media release, data from a Phase 1a/1b clinical trial of STK-012, were presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego.
    • 07 Mar 2024 According to a Synthekine media release, data from a Phase 1a/1b clinical trial of STK-012, will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place in San Diego, from April 5-10, 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top